Insmed (INSM) is Attracting Investor Attention — Here’s Why

Insmed Inc. (NASDAQ:INSM) is one of the 10 Stocks Posting Monster Gains Amid Market Downfall.

Shares of Insmed Inc. soared 20.58 percent on Thursday to close at $144.46 apiece following reports that French pharmaceutical firm Sanofi SA is planning to acquire the company in what could be the largest transaction so far in the biopharmaceutical industry.

A report by Bloomberg earlier in the day, citing people privy to the matter, said that Sanofi is currently in talks with its investment advisors to evaluate the potential transaction. The transaction is not yet guaranteed, with a decision potentially weeks away.

Photo by Mizuno K on pexels

Neither party confirmed nor denied the report, but ADRs of Sanofi SA dropped by 2.25 percent during the day.

The report followed the appointment of former Sanofi SA Chief Executive Officer Paul Hudson as one of the newest independent members of its board of directors last month, alongside Utpal Koppikar, Finance chief of Verily Health.

The planned acquisition aligns with Sanofi SA’s efforts to expand its presence in the respiratory market, particularly through Insmed Inc.’s Brinsupri, an FDA-approved treatment for non-cystic fibrosis bronchiectasis, and Arikayce, an inhaled antibiotic for MAC lung disease.

In the third quarter of the year, Brinsupri alone accounted for $400.1 million of Insmed Inc.’s total revenues, propelling a jump of 1,324 percent from only $28.1 million registered in the same period last year.

Arikayce accounted for $124.4 million, or a jump of 9 percent from $114.3 million year-on-year.

READ NEXT: Billionaire Stanley Druckenmiller’s New AI Warning and Top 10 Stock Picks

Follow Insider Monkey on Google News.